创新与研发



R&D


创新平台


长森药业专注具有自主知识产权及国际领先水平的创新药物的开发和医学转化，拥有一支由国际知名药学专家领衔，多名资深海归博士带队的高水平研发团队。

长森药业聚焦临床未竟需求，开发First in Class（FIC）、Best in Class（BIC）的创新产品，研发团队拥有从候选药物设计立项到药物上市的完整产业链经验，对免疫治疗具有深刻的理解和独特的洞见，针对自免疫相关的激酶等相关靶点深耕多年，擅长高活性与高选择性导向的创新药设计，研究与开发；同时，研发团队还具备丰富的大规模商业化生产的工艺设计和路线规划经验，对全球药物合作开发的深度理解及Licensing Out影响力和资源整合效率。

长森药业已有2款候选药物在临床研究阶段，研发管线储备丰富。

Innovation Platform

 

Longwood Biopharma focuses on the development and medical translation of world-class innovative drugs with independent IPR. The company has a high-level R&D team led by world-renowned experts and a number of senior PhD.

Our R&D team has a deep understanding and unique insight of immunotherapy, and has been working on autoimmune-related kinases and other related targets for many years, specializing in the design, research and development of highly active and highly selective innovative drugs. Furthermore, the R&D team has rich experience in drug synthesis process and route design for large scale manufacturing, in-depth understanding of global drug co-development, and the efficiency of Licensing Out and resource integration.

The company has strong R&D pipelines with two drug candidates in clinical research stage.

研发管线

 

长森药业聚焦自身免疫疾病、肿瘤免疫、抗病毒等领域的创新药研发与产业化，管线产品临床评估指标均达到国际领先水平，有望成为相关领域的重大突破FIC(first in class)。

研发项目
IPRs
疾病领域
靶点
适应症
IND
临床I期
临床II期
临床III期
NDA
LW231 ★
全球
乙肝
Capsid/cGAS
慢性乙肝
类风湿性关节炎(口服)
LW402
全球
自身免疫疾病
JAK1
特应性皮炎(口服)
白癜风(口服)
LW347
全球
肿瘤免疫治疗
PD-L1
肿瘤(口服)
LW108
全球
肿瘤、细胞凋亡
MDM2
肿瘤(口服)

Pipeline

 

Longwood Biopharma is focusing on the development and industrialization of innovative drugs for autoimmune diseases, tumor immunotherapy and anti-virus. With world-class performance in clinical evaluation, our pipelines are expected to become a major breakthrough in related fields (FIC, first in class).

R&D Projects
IPRs
Disease Field
Target
Indication
IND
Clinical Phase 1
Clinical Phase 2
Clinical Phase 3
NDA
LW231 ★
Global
Hepatitis B
Capsid/cGAS
Chronic hepatitis B
Rheumatoid arthritis(oral)
LW402
Global
Autoimmune diseases
JAK1
Atopic Dermatitis(Oral)
Vitiligo(Oral)
LW347
Global
Tumor,immunotherapy
PD-L1
tumour(oral)
LW108
Global
Tumor,cell apoptosis
MDM2
tumour(oral)

战略合作


联合全球产业伙伴，开展多层次合作，满足临床未竟需求


长森药业专注于研究开发及商业化创新免疫治疗药物，以满足中国和全球的临床需求。

长森药业秉承合作共赢的理念，通过与国内外知名高校、产业创新伙伴建立广泛的合作关系，积极参与全球药物创新与产业化合作。现阶段，长森药业期待来自全球的科研机构、产业伙伴在药物发现、临床研究、商业化等各阶段开展合作，并愿意在合作中开展任何形式的创新合作探索。

详情请发邮件至 info@lwbiopharma.com。

Collaboration

 

Multi-level Collaboration With Global Industry Partners To Meet Unmet Clinical Needs

Longwood Biopharma is focused on the R&D and commercialization of innovative immunotherapy drugs to meet clinical needs in China and globally.

Adhering to the concept of win-win cooperation, Longwood Biopharma actively participates in global drug innovation and industrialization cooperation by establishing extensive partnerships with renowned universities and industrial innovation partners at home and abroad. Presently, we are looking forward to cooperation with research institutions and industrial partners from all over the world in all stages of drug discovery, clinical research and commercialization, and are willing to explore any form of innovative cooperation in the collaboration.

For more information, please send an email to info@lwbiopharma.com